PROTEOME SCIENCES PLC

Board/Management Information • Dec 1, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5149Y

Proteome Sciences PLC

01 December 2014

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Retirement of Director and

appointment of new Company Secretary

1 December 2014: As foreshadowed in the Company's announcement on 30 September 2014 Mr. James Malthouse has today retired as a director of the Company and as Company Secretary.

Mr. Geoffrey Ellis, the Finance Director, has today been appointed as Company Secretary.

- Ends-

For further information please contact:

Proteome Sciences plc
Christopher Pearce, Executive Chairman
Dr. Ian Pike, Chief Operating Officer	Tel: +44 (0)1932 865065
Geoff Ellis, Finance Director
Nominated Adviser
Cenkos
Mark Connelly/Callum Davidson finnCap Geoff Nash	Tel: +44 (0)20 7397 8900 Tel : +44 (0)20 7220 0563
Public Relations
IKON Associates	Email: adrian@ikonassociates.com
Adrian Shaw	Tel: +44 (0)1483 271291
	Mobile +44(0)7979 900733

Notes for editors:

About Proteome Sciences plc (www.proteomics.com)

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.

Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.

The Company's PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAEFLFBZLFFFBB